Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,104 Deaths · 90,516 Hospitalizations · 119,465 Urgent Care · 200,470 Doctor Office Visits · 2,538 Anaphylaxis · 6,382 Bell's Palsy · 2,067 Miscarriages · 9,477 Heart Attacks · 28,706 Myocarditis · 18,506 Permanently Disabled · 9,306 Thrombocytopenia · 15,329 Life Threatening · 36,838 Severe Allergic Reaction · 8,237 Shingles · 5,297 Myocarditis/Pericarditis · 3,723 Thrombocytopenia/Low Platelet ·
·
19,104 Deaths · 90,516 Hospitalizations · 119,465 Urgent Care · 200,470 Doctor Office Visits · 2,538 Anaphylaxis · 6,382 Bell's Palsy · 2,067 Miscarriages · 9,477 Heart Attacks · 28,706 Myocarditis · 18,506 Permanently Disabled · 9,306 Thrombocytopenia · 15,329 Life Threatening · 36,838 Severe Allergic Reaction · 8,237 Shingles · 5,297 Myocarditis/Pericarditis · 3,723 Thrombocytopenia/Low Platelet ·
·